CDIP1

Across TCGA pan-cancer cohorts, CDIP1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDIP1 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CDIP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDIP1 expression acts as an unfavorable survival marker.

BRCA, SKCM, and BLCA are the cancer types where CDIP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.583	0.924	<.001	36	view →
SKCM	OS	Median	All	0.230	0.783	.002	30	view →
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
COAD	OS	Median	All	0.111	0.871	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDIP1–BRCA (OS)

Open the BRCA breakdown →